Press Releases

3 Notable Runners: Union Pacific Corporation (UNP), American Airlines Group Inc. (AAL), Mylan N.V. (MYL)

earningswp22

Union Pacific Corporation (UNP) continued its upward trend with the stock climbing 1.56% or $1.7 to close the day at $110.42 on higher than average trading volume of 5.14M shares, compared to its three month average trading volume of 4.1M. The Omaha Nebraska 68179 based company has been outperforming the railroads companies by 23.4969% for last three months and its recent gains have pushed the stock slightly up 6.5% YTD, versus the railroads industry which is up 23.8% for the same period. The RSI of 70.3 indicates the stock is overbought at the current levels, sell for now.

Union Pacific Corporation, through its subsidiary, Union Pacific Railroad Company, operates railroads in the United States. It offers freight transportation services for agricultural products, including grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals comprising industrial chemicals, plastics, fertilizers, petroleum and liquid petroleum gases, crude oil, and soda ash. The company also provides transportation services for coal and petroleum coke; industrial products consisting of construction products, minerals, consumer goods, metals, lumber, paper, and other miscellaneous products; and intermodal import and export containers and trailers. Union Pacific Corporation’s rail network includes 32,084 route miles linking the Pacific Coast and Gulf Coast ports with the Midwest and eastern United States gateways. The company was founded in 1862 and is headquartered in Omaha, Nebraska.

American Airlines Group Inc. (AAL) had a light trading with around 5.14M shares changing hands compared to its three month average trading volume of 6.3M. The stock traded between $47.61 and $48.21 before closing at the price of $47.91 with 0.78% change on the day. The Fort Worth Texas 76155 based company is currently trading 93.86% above its 52 week low of $24.85 and -5.39% below its 52 week high of $50.64. Both the RSI indicator and target price of 52.97 and $53.73 respectively, lead us to believe that it should be put on hold over the coming weeks.

American Airlines Group Inc., through its subsidiaries, operates in the airline industry. As of December 31, 2015, the company operated a mainline fleet of 946 aircraft. It serves 350 destinations in approximately 50 countries. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1934 and is headquartered in Fort Worth, Texas.

Mylan N.V. (MYL) traded within a range of $35.98 to $36.64 after opening the day at $36. The company has seen its stock decrease in value by -4.38% so far this year. The stock was up close to 1.87% on light volume in last trading session and closed at $36.48 per share. After the recent gain, the stock is currently holding -32.73% below its 52 week high of $53.92 and 8.57% above its 12-month low of $33.6. The shares are down by over -2.88% in the last three months, and the RSI indicator value of 43.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

 

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *